Nektar Therapeutics

NKTR

US6402681083

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.76 ^USD	+10.00%		+12.10%	+211.50%

May. 09	Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M	MT
May. 09	Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024

Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 08, 2023 at 04:15 pm EDT

Nektar Therapeutics reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 20.5 million compared to USD 21.59 million a year ago. Net loss was USD 51.12 million compared to USD 159.07 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.85 a year ago.
For the six months, revenue was USD 42.09 million compared to USD 46.41 million a year ago. Net loss was USD 188.14 million compared to USD 249.46 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 1.34 a year ago.

Latest news about Nektar Therapeutics

Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M	May. 09	MT
Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024	May. 09
Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	Apr. 24	CI
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	Mar. 18	CI
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	Mar. 05	MT
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating	Mar. 05	MT
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	Mar. 05	CI
Transcript : Nektar Therapeutics, Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M	Mar. 04	MT
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 04	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC	Mar. 03	CI
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	Jan. 22	MT
Transcript : Nektar Therapeutics Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	Jan. 10
Nektar Therapeutics(NasdaqCM:NKTR) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255	Dec. 12	MT
North American Morning Briefing : Investors Weigh -2-	Nov. 10	DJ
TD Cowen Upgrades Nektar Therapeutics to Outperform From Market Perform	Nov. 09	MT
Transcript : Nektar Therapeutics, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q3 Revenue $24.1M, vs. Street Est of $21.3M	Nov. 07	MT
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Nektar Therapeutics Says Rezpegaldesleukin Trial Data Showed 'Consistent Benefit' to Treat Atopic Dermatitis	23-10-13	MT
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy	23-10-13	CI

Chart Nektar Therapeutics

Duration

Period

More charts

Company Profile

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the bodyâs immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the bodyâs innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.

Sector

Pharmaceuticals

Calendar

2024-06-05 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Nektar Therapeutics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.76 USD

Average target price

1.6 USD

Spread / Average Target

-9.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEKTAR THERAPEUTICS	+211.50%	323M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals